TQ-B3139

· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for TQ-B3139, covering 2019-10-30 to 2019-10-30. Get the full timeline:

Most recent: Clinical Trial Update: Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib [Phase 2]

See pricing